Octreotide Infusion Dosage
For acute variceal hemorrhage, administer octreotide as a 50 mcg IV bolus followed by continuous infusion at 50 mcg/hour for 2-5 days; for carcinoid crisis prevention during surgery, use 50 mcg/hour IV infusion; and for carcinoid syndrome symptom control, start with 50-100 mcg subcutaneously 2-3 times daily, titrating up to a maximum of 1500 mcg/day. 1, 2
Acute Variceal Hemorrhage
The most recent and highest-quality evidence comes from the 2024 AGA Clinical Practice Update and 2017 AASLD guidelines, which provide clear dosing algorithms 3, 1:
- Initial bolus: 50 mcg IV (can be repeated within the first hour if ongoing bleeding)
- Continuous infusion: 50 mcg/hour IV
- Duration: 2-5 days after endoscopic hemostasis
Key algorithmic approach:
- Start octreotide immediately upon suspicion of variceal bleeding, even before endoscopy 1, 4
- Administer alongside antibiotics (ceftriaxone 1g IV daily) 1
- Continue infusion for 2-5 days post-endoscopy to prevent early rebleeding 1, 3
Duration considerations: Recent high-quality evidence suggests shorter durations may be non-inferior. The 2024 AGA update notes that 2-day courses may be sufficient in selected Child-Pugh A and B patients without active bleeding at endoscopy 3. Multiple recent RCTs (2025-2026) demonstrate that 24-72 hour infusions are non-inferior to 5-day courses for preventing rebleeding 5, 6, 7. However, the established guideline recommendation remains 2-5 days, with shortening to 2 days reasonable only in lower-risk patients 3.
Critical pitfall: Octreotide is the preferred vasoactive drug in the United States due to its superior safety profile compared to terlipressin/vasopressin, which carry 2.39-fold higher adverse event rates including cardiac complications 3.
Carcinoid Syndrome and Neuroendocrine Tumors
Chronic Symptom Management
For routine carcinoid syndrome control 8, 2:
- Starting dose: 50-100 mcg subcutaneously 2-3 times daily
- Typical maintenance: 100 mcg subcutaneously 3 times daily
- Maximum: 1500 mcg/day (though doses >750 mcg/day have limited experience)
- Median effective dose: 450 mcg/day in divided doses
Practical note: Long-acting formulations (octreotide LAR 20-30 mg IM every 4 weeks) are preferred for chronic management, with short-acting octreotide (150-250 mcg subcutaneously 3 times daily) added for breakthrough symptoms 9, 10.
Perioperative/Crisis Management
For carcinoid crisis prevention during surgery or high-stress procedures 8, 11:
- Infusion rate: 50 mcg/hour IV continuously
- Timing: Start 12 hours before procedure, continue during, and for 48 hours after
- Alternative high-dose protocol: Some centers use 500 mcg IV bolus followed by 500 mcg/hour infusion for high-risk NET patients undergoing surgery 11
Critical consideration: This aggressive perioperative dosing prevents life-threatening cardiovascular carcinoid crises during anesthesia, surgical manipulation, or hepatic artery embolization 8.
Postoperative Pancreatic Fistula Prevention
While evidence exists for octreotide in preventing pancreatic fistula, the data show inconsistent efficacy, particularly for pancreaticoduodenectomy 12. The FDA-approved dosing for off-label use is:
- Dose: 100-150 mcg subcutaneously 3 times daily
- Duration: 5-7 days perioperatively, starting at least 1 hour before surgery 13
Important caveat: Recent network meta-analysis (2025) suggests octreotide's benefit may be limited to non-pancreaticoduodenectomy resections, with questionable efficacy in PD specifically 12. This indication should be considered carefully on a case-by-case basis.
Administration Considerations
Compatibility and preparation 2:
- Compatible with sterile isotonic saline or dextrose 5% for 24 hours
- Can be diluted in 50-200 mL and infused over 15-30 minutes, or given as IV push over 3 minutes
- Not compatible with Total Parenteral Nutrition due to glycosyl conjugate formation
- For emergency situations (carcinoid crisis), may be given as rapid IV bolus
Monitoring: Rotate subcutaneous injection sites systematically to minimize local reactions. Use smallest volume necessary to reduce injection pain 2.